Early Breast Cancer Clinical Trials

33 recruitingLast updated: June 17, 2026

There are 33 actively recruiting early breast cancer clinical trials across 51 countries. Studies span Phase 2, Not Applicable, Phase 3, Phase 1. Top locations include Taipei, Taiwan, Berlin, Germany, Beijing, China. Updated daily from ClinicalTrials.gov.


Early Breast Cancer Trials at a Glance

33 actively recruiting trials for early breast cancer are listed on ClinicalTrialsFinder across 6 cities in 51 countries. The largest study group is Phase 2 with 10 trials, with the heaviest enrollment activity in Taipei, Berlin, and Beijing. Lead sponsors running early breast cancer studies include Second Affiliated Hospital, School of Medicine, Zhejiang University, Novartis Pharmaceuticals, and AstraZeneca.

Browse early breast cancer trials by phase

Treatments under study

About Early Breast Cancer Clinical Trials

Looking for clinical trials for Early Breast Cancer? There are currently 17 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Early Breast Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Early Breast Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 33 trials

Recruiting
Phase 3

Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

Early Breast Cancer
Novartis Pharmaceuticals1,400 enrolled217 locationsNCT05827081
Recruiting
Phase 2

NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer

HER2 Positive Early Breast Cancer
West German Study Group702 enrolled44 locationsNCT05704829
Recruiting
Phase 3

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

Breast Cancer (Early Breast Cancer)
AstraZeneca5,500 enrolled794 locationsNCT05952557
Recruiting
Phase 2

Fovinaciclib Plus Aromatase Inhibitors and Dual HER2 Blockade in a Response-Adapted Neoadjuvant Strategy for HR-Positive/HER2-Positive Early Breast Cancer

HR+/HER2- Early Breast Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University100 enrolled3 locationsNCT07616427
Recruiting
Phase 2

Efficacy and Safety of Culmerciclib Plus Aromatase Inhibitors in a Response-Adapted Neoadjuvant Strategy for Highly Proliferative ER-Positive/HER2-Negative Breast Cancer

HR+/HER2- Early Breast Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University45 enrolled1 locationNCT07616453
Recruiting

Patient Relevant Outcomes Improvement Program in High Risk Hormone Receptor Positive (HR+) Breast Cancer

HR+/HER2- Early Breast Cancer
Institut fuer Frauengesundheit200 enrolled1 locationNCT07531693
Recruiting
Phase 3

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy

Breast Cancer (Early Breast Cancer)
AstraZeneca4,300 enrolled711 locationsNCT05774951
Recruiting
Not Applicable

Refusal of Sentinel Lymph Node Biopsy in Patients With Luminal A Subtype Early Breast Cancer

Early Breast Cancer
N.N. Petrov National Medical Research Center of Oncology100 enrolled1 locationNCT07579286
Recruiting
Not Applicable

Luminal Breast Cancer Cryoablation

Breast CancerBreast Cancer (Early Breast Cancer)
Lucía Graña López140 enrolled1 locationNCT07447414
Recruiting

Real-life Evaluation of Endopredict® in Early HR+/HER2- Breast Cancer

HER2-negative Breast CancerBreast Cancer (Early Breast Cancer)Breast Cancer Survivors+2 more
Assistance Publique - Hôpitaux de Paris1,000 enrolled1 locationNCT07379918
Recruiting

Adherence to Aromatase Inhibitors ± Abemaciclib Treatment in Patients With Early-stage HER2-negative Breast Cancer

HER2-negative Breast CancerEarly Breast CancerHormone Receptor Positive Tumor
Institute of Oncology Ljubljana319 enrolled1 locationNCT06650423
Recruiting
Not Applicable

Tailored Exercise to Reduce Aromatase Inhibitor Associated Musculoskeletal Symptoms

Patients With Early Breast Cancer Who Initiating Adjuvant Aromatase Inhibitor
Mahidol University206 enrolled1 locationNCT07448558
Recruiting
Phase 2

A Study on the Use of Fluzoparib Combined With Chemotherapy for Neoadjuvant Treatment of HRD-positive, HR+/HER2- Breast Cancer

HR+/HER2- Early Breast Cancer
Xijing Hospital28 enrolled1 locationNCT07162051
Recruiting
Not Applicable

Breast Cancer Organelle Properties and Protein Expression Atlas in the Three Immunohistochemical Subtypes of Breast Cancers

Metastatic Breast CancerEarly Breast Cancer
Institut Claudius Regaud1,050 enrolled1 locationNCT07233928
Recruiting
Not Applicable

Evaluation of the Effectiveness of Managing Chemotherapy Side Effects Using ePRO and a Standardized Telenursing Program for Cancer Patients

Advanced Breast CancerEarly Breast CancerAdvanced Lung Cancer+5 more
Ulsan University Hospital414 enrolled5 locationsNCT07405931
Recruiting

RWE Non-Interventional Prospective Study of Ribociclib Effectiveness and Safety in Patients With HR+/HER2- Early Breast Cancer in Saudi Arabia

HR+/HER2- Early Breast Cancer
Novartis Pharmaceuticals177 enrolled2 locationsNCT06797531
Recruiting

Praegnant Breast Cancer: Early/Advanced/Metastatic

Breast Cancer (Early Breast Cancer)Advanced/Metastatic Breast Cancer
University Hospital Tuebingen13,500 enrolled61 locationsNCT02338167
Recruiting
Phase 2

Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast Cancer

HER2 Positive Early Breast Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University200 enrolled1 locationNCT07340398
Recruiting

Validation of the Oncoliq Test for the Early Detection of Breast Cancer.

Breast Cancer FemaleBreast Cancer DetectionBreast Cancer Early Stage Breast Cancer (Stage 1-3)+4 more
Oncoliq US Inc300 enrolled1 locationNCT07331506
Recruiting
Phase 2

Mediterranean Diet and Inequality in Early Breast Cancer

Early Breast Cancer
Esbjerg Hospital - University Hospital of Southern Denmark105 enrolled2 locationsNCT07007169